FDA newly confirmed to be presenting on the program!
MedPharm is the world leading specialist pharmaceutical development company, committed to the creation and development of bespoke topical and transdermal formulations for application to the skin, nail, mucous membranes, eye, nose and lung. Alongside developing its own patented dermal drug delivery technologies, MedPharm uses its experience to support customers through regulatory approval previously resulting in biowaivers for generic submissions from regulatory authorities and marketing authorisations for over 60 products in the US and Europe.
Tergus is a full-service topical pharmaceutical research, development, testing and manufacturing company. The company is an industry leader for more than 20 years with a state-of-the-art facility in Durham, North Carolina. The company has a long and stellar reputation for delivering quality and results for clients from formulation through manufacturing, which is why people say, “Think Topical. Think Tergus.”
San Diego based, Therapeutics, Inc., The Dermatology CRO was founded in 1997. Approximately 90% of our activities are focused on developing dermatology products. TI is the only dermatology-focused CRO that provides all services required to move a product concept through non-clinical and clinical stages to FDA approval. During the last 5 years: TI managed >11,000 subjects in >90 clinical studies and filed >20 INDs and IDEs in a variety of drug, device and biologic programs.
CPL is a leading contract development and manufacturing organization providing product development and commercial manufacturing of non-sterile liquid and semisolid pharmaceutical and regulated OTC products. Our facilities are registered by FDA and Health Canada and maintain an outstanding record of regulatory compliance. CPL is a reputable contract manufacturer known to provide high quality product with exceptional service. By offering a full-spectrum partnership – from development to commercial production – CPL creates strategic, long-term relationships with our customers.
Based in Gothenburg Sweden, Fluicell is a public company that has commercialized single-cell discovery platforms for life science to study single cells, primarily in the field of drug development. Fluicell’s existing products are the research tools Biopen® and Dynaflow® Resolve, which today allow researchers to investigate the effects of drugs on individual cells at a unique level of detail. Fluicell is also developing a unique high-resolution bioprinting technology in both 2D and 3D under the name Biopixlar™. With this system, complex tissue-like structures can be created where positioning of individual cells can be controlled.
DPT, a Mylan company, is a leading contract development and manufacturing organization, recognized for its excellence in semi-solid and liquid dosage forms. Backed by a team of approximately 1,000 employees in San Antonio, Texas, DPT has unmatched experience, resources and capacity to efficiently serve your pharmaceutical development and manufacturing needs – no matter the scope. From concept to commercialization, DPT remains committed to exceeding expectations for quality and service.
Dow Development Lab’s core expertise is in the design, development and manufacture of topical drug products for dermatology. The formulation, analytical, production, quality, and clinical labeling groups have decades of experience moving products quickly toward regulatory approval. Always with the patient in mind, products are designed to be disease-compatible and cosmetically elegant. Dow Development Labs works seamlessly with its parent company Symbio, a specialty clinical CRO, to rapidly advance client dermatological programs through all stages of clinical development.
Bioskin is a leading CRO with unique understanding and capabilities for both early and late phase dermatological clinical trials. Recognized by global companies as a valuable partner in studies for drugs, medical devices, food supplements and advanced cosmetics since 1992, bioskin offers early phase safety and Proof-of-Concept studies, vasoconstrictor assays according to FDA guideline, global Phase II – IV trials for NCEs, new formulations with known actives as well as consulting in the field of dermatology.